TY - JOUR
T1 - Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease
AU - Tsai, Hsiu Ting
AU - Lee, Tsung Hsien
AU - Yang, Shun Fa
AU - Lin, Long Yau
AU - Tee, Yi Torng
AU - Wang, Po Hui
N1 - Funding Information:
Supported by grants ( NSC-98-2314-B-040-014-MY3 and NSC-99-2314-B-040-008-MY3 ) from the National Science Council, Taiwan .
PY - 2013/2
Y1 - 2013/2
N2 - Objective: To estimate the expression of plasma soluble E-cadherin and the gene polymorphism in patients with pelvic inflammatory disease (PID). Design: Hospital-based case-control study. Setting: University hospital. Patient(s): Sixty-four women with PID. Intervention(s): Blood specimen collection from patients before and after they received treatment. Main Outcome Measure(s): Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were respectively used to measure the plasma soluble E-cadherin level and E-cadherin polymorphism. Result(s): The level of plasma E-cadherin was significantly elevated in patients with PID as compared with that in normal controls; it decreased significantly after treatment when compared with levels noted in the same patients before they received treatment. When the cutoff level of plasma E-cadherin level was set to 20.22 ng/mL on the basis of receiver-operating characteristic curve (ROC), the sensitivity, specificity, and the area under the curve of plasma E-cadherin level for predicting PID were 0.81, 0.80, and 0.835 (95% confidence interval 0.76-0.90), respectively. The adjusted odds ratio for age, white blood cell count, and C-reactive protein levels was 19.66 (5.48-70.47). Conclusion(s): Elevated plasma soluble E-cadherin expression was involved in the pathogenesis of PID and is useful for the diagnosis of PID.
AB - Objective: To estimate the expression of plasma soluble E-cadherin and the gene polymorphism in patients with pelvic inflammatory disease (PID). Design: Hospital-based case-control study. Setting: University hospital. Patient(s): Sixty-four women with PID. Intervention(s): Blood specimen collection from patients before and after they received treatment. Main Outcome Measure(s): Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were respectively used to measure the plasma soluble E-cadherin level and E-cadherin polymorphism. Result(s): The level of plasma E-cadherin was significantly elevated in patients with PID as compared with that in normal controls; it decreased significantly after treatment when compared with levels noted in the same patients before they received treatment. When the cutoff level of plasma E-cadherin level was set to 20.22 ng/mL on the basis of receiver-operating characteristic curve (ROC), the sensitivity, specificity, and the area under the curve of plasma E-cadherin level for predicting PID were 0.81, 0.80, and 0.835 (95% confidence interval 0.76-0.90), respectively. The adjusted odds ratio for age, white blood cell count, and C-reactive protein levels was 19.66 (5.48-70.47). Conclusion(s): Elevated plasma soluble E-cadherin expression was involved in the pathogenesis of PID and is useful for the diagnosis of PID.
KW - E-cadherin
KW - pelvic inflammatory disease (PID)
KW - single nucleotide polymorphism (SNP)
UR - http://www.scopus.com/inward/record.url?scp=84873293551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873293551&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2012.10.010
DO - 10.1016/j.fertnstert.2012.10.010
M3 - Article
C2 - 23122825
AN - SCOPUS:84873293551
SN - 0015-0282
VL - 99
SP - 490
EP - 495
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 2
ER -